Benitec Biopharma Inc.

- Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal Muscular Dystrophy (OPMD) - 100% of Patients treated with BB-301 across both doses are formal Responders to therapy - Interim clinical results for Patients treated with high dose BB-301 demonstrate greater relative improvements at the 3-month post-treatment time-point in throat emptying ability (assessed by videofluoroscopic evaluation of post-swallow food…

Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report) shares passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $11.14 and traded as low as $8.00. Benitec Biopharma shares last traded at $8.36, with a volume of 194,119 shares. Analyst Ratings Changes Several analysts recently

The BB-301 pivotal trial remains on track to begin in mid-2027 Discussions regarding an open-label, single-arm, pivotal study for BB-301 are ongoing, and based on these discussions, the FDA requested additional available data, including data from the Benitec-sponsored OPMD Natural History Study Final pivotal study design expected to be confirmed in 1Q 2027 Benitec will present interim clinical results from the ongoing BB-301 Phase 1b/2a study as a late-breaking poster presentation, which will en…

Benitec Biopharma Limited (NASDAQ: BNTC - Get Free Report)'s share price crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $12.08 and traded as low as $9.65. Benitec Biopharma shares last traded at $9.75, with a volume of 110,967 shares changing hands. Analyst Ratings Changes A number

Benitec Biopharma (BNTC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Benitec Biopharma (NASDAQ: BNTC - Get Free Report) is expected to announce its Q4 2026 results before the market opens on Monday, September 28th. Analysts expect Benitec Biopharma to announce earnings of ($0.2686) per share for the quarter. Investors may review the information on the company's upcoming Q4 2026 earning summary page for the latest details

All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated A Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in October Additional interim clinical study results from the ongoing BB-301 Phase 1b/2a trial have been accepted for late-breakin…

AWM Investment Company Inc. acquired a new position in Benitec Biopharma Limited (NASDAQ: BNTC) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 187,977 shares of the biotechnology company's stock, valued at approximately $2,515,000. AWM Investment Company Inc. owned about 0.55% of